Issue Date: October 5, 2012
Issued by: Center for Drug Evaluation and Research
Topic(s): Clinical – Antimicrobial
Status: Final
Acute Bacterial Sinusitis — Developing Antimicrobial Drugs for Treatment
The purpose of this guidance is to assist sponsors in the clinical development of drugs2 for the treatment of acute bacterial sinusitis (ABS). This guidance defines ABS as “inflammation of the paranasal sinuses as a result of the presence of a bacterial pathogen within the sinus space when the duration of illness is less than 4 weeks.”
Download the Guidance Document
